DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his...
Beam Wellness was born out of the CEO's experience as a marketer in the cosmetic industry. It's now being incubated at Health Wildcatters in...
John P. Pigott, MD, FACS, currently serves as Chief Innovations Officer/Strategic Business Development for ProMedica and ProMedica Innovations, where he works with thought leaders...
